Close

Endo Pharmaceuticals Holdings (ENDP) Tops Q3 EPS by 6c, Reaffirms Guidance

October 27, 2011 7:47 AM EDT
Endo Pharmaceuticals Holdings (NASDAQ: ENDP) reported Q3 EPS of $1.25, $0.06 better than the analyst estimate of $1.19. Revenue for the quarter came in at $759 million versus the consensus estimate of $750.26 million.

Company reaffirms 2011 guidance for revenue of $2.72 to $2.80 billion and adjusted diluted EPS of $4.55 to $4.65; now expects reported or GAAP diluted EPS of $1.87 to $1.97.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance